metronidazole has been researched along with Precancerous Conditions in 7 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Precancerous Conditions: Pathological conditions that tend eventually to become malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among the 18 new cases of gastric cancers that developed, no overall reduction was observed in participants who received H pylori eradication treatment (n = 7) compared with those who did not (n = 11) (P =." | 2.71 | Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. ( Chen, JS; Ching, CK; Feng, RE; Fong, DY; Ho, J; Hu, WH; Lai, KC; Lam, SK; Leung, SY; Wong, BC; Wong, WM; Yuen, ST; Zheng, TT, 2004) |
| "pylori-induced gastric cancer, irrespective of the timing of antibiotic administration." | 1.42 | Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. ( Aponte-Pieras, JR; Lee, DS; Morrissey, R; Moss, SF; Rogers, AB; Zhang, S, 2015) |
| "Endoscopy after ER detected no new gastric cancers in these patients." | 1.30 | Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. ( Haruma, K; Kajiyama, G; Mashiba, H; Mukai, T; Okamoto, S; Sasaki, N; Sumii, K; Taniyama, K; Uemura, N; Yamaguchi, S, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, S | 1 |
| Lee, DS | 1 |
| Morrissey, R | 1 |
| Aponte-Pieras, JR | 1 |
| Rogers, AB | 1 |
| Moss, SF | 1 |
| Wong, BC | 1 |
| Lam, SK | 1 |
| Wong, WM | 1 |
| Chen, JS | 2 |
| Zheng, TT | 1 |
| Feng, RE | 1 |
| Lai, KC | 1 |
| Hu, WH | 1 |
| Yuen, ST | 1 |
| Leung, SY | 1 |
| Fong, DY | 1 |
| Ho, J | 1 |
| Ching, CK | 1 |
| Camargo, MC | 1 |
| Piazuelo, MB | 1 |
| Mera, RM | 1 |
| Fontham, ET | 1 |
| Delgado, AG | 1 |
| Yepez, MC | 1 |
| Ceron, C | 1 |
| Bravo, LE | 2 |
| Bravo, JC | 2 |
| Correa, P | 2 |
| Muñoz, N | 1 |
| Vivas, J | 1 |
| Buiatti, E | 1 |
| Kato, I | 1 |
| Oliver, W | 1 |
| Uemura, N | 1 |
| Mukai, T | 1 |
| Okamoto, S | 1 |
| Yamaguchi, S | 1 |
| Mashiba, H | 1 |
| Taniyama, K | 1 |
| Sasaki, N | 1 |
| Haruma, K | 1 |
| Sumii, K | 1 |
| Kajiyama, G | 1 |
| van Doorn, LJ | 1 |
| Ruiz, B | 1 |
| Realpe, JL | 1 |
| Minucci, D | 1 |
| Guida, G | 1 |
| Rabasso, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
2 trials available for metronidazole and Precancerous Conditions
| Article | Year |
|---|---|
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
Chemoprevention trial on precancerous lesions of the stomach in Venezuela: summary of study design and baseline data.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anticarcinogenic Agents; Antioxidants; Clarithromyc | 1996 |
5 other studies available for metronidazole and Precancerous Conditions
| Article | Year |
|---|---|
Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model.
Topics: Animals; Anti-Bacterial Agents; Chemokine CXCL10; Chemokine CXCL9; Clarithromycin; Gastric Mucosa; G | 2015 |
Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Colombia; Drug Therapy, Combination; Female; Follow-Up | 2007 |
Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Biopsy; Clarithromycin; Combined Modality Therapy; Dose | 1997 |
Unsuccessful treatment results in survival of less virulent genotypes of Helicobacter pylori in Colombian patients.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Chemoprevention; Colombia; Follow-Up Studies; | 2000 |
[Dysplasia and carcinoma in situ of the uterine cervix. Outcome of several cases].
Topics: Adult; Antineoplastic Agents; Carcinoma in Situ; Female; Humans; Metronidazole; Nystatin; Precancero | 1975 |